You are here: Industry Insights > CAR-T

News List

Lilly eyes more cancer deals, but wary of CAR-T, gene therapy firstwordpharma
January 13, 2019
Eli Lilly CEO Dave Ricks said that as the company looks for deals to enhance its pipeline of future treatments it will leave CAR-T therapies for cancer and gene therapy for rare diseases to others, as reported Yahoo Finance Friday.
Belldegrun's Allogene looks to poach veteran biotech analyst for CFO: Stat fiercebiotech
May 08, 2018
Former Kite execs Arie Belldegrun and David Chang splashed back onto the scene last month with a new startup, an array of off-the-shelf CAR-T assets and $300 million to bankroll it all. Now, Stat reports, Belldegrun is looking to sign on Cowen analyst Eri
FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma worldpharmanews
October 23, 2017
The U.S. Food and Drug Administration approved Yescarta, a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment.
FDA Approves Second CAR-T Cell Therapy and first for certain types of NHL americanpharmaceuticacreview
October 20, 2017
has become the second gene therapy to be approved by the US Food and Drug Administration, offering a new treatment approach for patients with certain types of large B-cell lymphoma.
Averting toxic side effects from CAR-T cancer treatments fiercebiotech
October 13, 2017
As excited as the oncology community is about the recent approval of Kymriah, Novartis’ CAR-T treatment for some patients with lymphoma, concerns about side effects remain.